Prospectively, RPPA analysis of key EV (phospho-)proteins such as those involved in the EGFR, mechanistic target of rapamycin (mTOR) and vascular endothelial growth factor receptor (VEGFR) pathways, allow cancer- and patient-specific adoption of treatment strategies (Fig. 3E, F). This evidence concerns the gene MTOR and cancer.